Bortezomib

• Used in the treatment of multiple myeloma as part of an appropriate cancer treatment plan
• May also be used for certain cases of mantle cell lymphoma, depending on the patient's condition and treatment protocol
• Helps target cancer cells by inhibiting the proteasome, a cellular system involved in protein breakdown and cell survival
• May help slow the growth and progression of cancer cells in appropriate patients
• Can be used in combination with other anticancer medicines as determined by an oncologist
• Supports comprehensive cancer treatment under specialist medical supervision

• Administration: Bortezomib is administered by a qualified healthcare professional through intravenous (IV) injection or subcutaneous injection, depending on the prescribed treatment protocol.
• Dosage: The dose and treatment schedule are determined by the type of cancer, treatment regimen, medical condition, and response to therapy.
• Do not self-administer this medicine.
• Treatment should be given according to the schedule recommended by your oncologist or healthcare professional.
• Follow all instructions regarding accompanying medicines and supportive treatment during therapy.

• Use only under the supervision of a qualified oncologist or healthcare professional.
• Inform your doctor if you have liver problems, kidney problems, nerve disorders, or low blood cell counts.
• Bortezomib may affect blood cell counts. Regular blood tests and medical monitoring may be required during treatment.
• Inform your healthcare professional if you develop numbness, tingling, burning pain, weakness, unusual bleeding, fever, or signs of infection.
• Your doctor may monitor liver function and other blood parameters throughout treatment.
• Maintain adequate fluid intake as advised by your healthcare professional.
• Inform your doctor about all medicines, supplements, and herbal products you are taking, as drug interactions may occur.
• Avoid alcohol or discuss alcohol consumption with your healthcare professional during treatment.
• Seek immediate medical attention if you experience severe allergic reactions, difficulty breathing, significant bleeding, or other serious symptoms.

• Store Bortezomib according to the specific product label and manufacturer's instructions.
• If the product requires refrigeration, store it between 2°C and 8°C and do not freeze.
• Protect the medicine from direct sunlight and excessive moisture.
• Keep out of reach of children and unauthorized persons.
• Reconstituted solutions should be handled and stored only according to the manufacturer's instructions by qualified healthcare professionals.

Bortezomib is a prescription anticancer medicine used in the management of multiple myeloma and certain cases of mantle cell lymphoma. It should be administered only by qualified healthcare professionals under the supervision of an oncologist.
The dosage, treatment schedule, route of administration, and combination with other medicines depend on the patient's condition and prescribed treatment protocol. Regular medical monitoring may be required during therapy.
Individual treatment response may vary. Always follow your oncologist's instructions regarding dosage, treatment schedule, monitoring, and supportive care.